(NP (-LRB- -LCB-) (NP-COOD (NP (NP (NNS Changes)) (PP (IN in) (NP (NP (JJ leucocytic) (NN estrogen) (NN receptor) (NNS levels)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ climacteric) (NN syndrome)))))))) (CC and) (NP (NP (JJ therapeutic) (NN effect)) (PP (IN of) (NP (FW liuwei) (FW dihuang) (NNS pills))))) (-RRB- -RCB-))
(S (NP-SBJ-24 (NP (DT The) (NNS numbers)) (PP (IN of) (NP (NP (NP (NN estrogen) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN ER)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (JJ human) (JJ peripheral) (NNS leucocytes)) (PP (IN in) (NP (NP (CD 22) (NNS women)) (PP (IN with) (NP (JJ climacteric) (NN syndrome)))))))))) (VP (VBD were) (VP (VBN measured) (NP (-NONE- *-24)) (PP (IN by) (NP (NN radioligand) (NN method))))) (. .))
(S (NP-SBJ-25 (DT The) (NNS results)) (VP (VBD were) (VP (VBN compared) (NP (-NONE- *-25)) (PP (IN with) (NP (NP (DT those)) (PP (IN of) (NP (CD 12) (JJ normal) (JJ child-bearing-age) (NNS women))))))) (. .))
(S (NP-SBJ (PRP It)) (VP (VBD wat) (VP (VBN found) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NNS contents)) (PP (IN of) (NP (NP (JJ leucocytic) (NN ER)) (PP (IN in) (NP (JJ climacteric) (NN syndrome) (NNS patients)))))) (VP (VBD were) (ADJP-PRD (ADJP (RB significantly) (JJR lower)) (PP (IN than) (NP (JJ normal) (JJ child-bearing-age) (NNS women))))))))) (. .))
(S (NP-SBJ-26 (DT The) (NNS authors)) (VP (VBD used) (NP (NP (DT a) (JJ Chinese) (NN prescription)) (: --) (NP (NP (FW Liuwei) (FW Dihuang) (NNS Pills)) (PRN (-LRB- -LRB-) (NP (NN LDP)) (-RRB- -RRB-)))) (S (NP-SBJ (-NONE- *-26)) (VP (TO to) (VP (VB treat) (NP (DT the) (NNS patients)) (PP-TMP (IN for) (NP (CD 2) (NNS months))))))) (. .))
(S (NP-SBJ-27 (NP (DT The) (NNS numbers)) (PP (IN of) (NP (JJ leucocytic) (NN ER)))) (VP (VBD were) (ADVP (RB significantly)) (VP (VBN increased) (NP (-NONE- *-27)) (PP-TMP (IN after) (NP (NN treatment))))) (. .))
(S (NP-SBJ (DT The) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ (NP (NN decrease)) (PP (IN of) (NP (NP (NN ER) (NNS levels)) (PP (IN in) (NP (NN cell)))))) (VP (MD may) (VP (VB involve) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (JJ climacteric) (NN syndrome)))))))))) (. .))
(S (NP-SBJ (NN LDP)) (VP-COOD (CONJP (RB not) (RB only)) (VP (VBZ increases) (NP (NN plasma) (NN estradiol) (NNS levels))) (, ,) (CONJP (CC but) (RB also)) (VP (VBZ increases) (NP (DT the) (JJ leucocytic) (NN ER) (NNS levels)))) (. .))
(S (NP-SBJ (DT This)) (VP (MD may) (VP (VB be) (NP-PRD (NP (DT the) (NN basis)) (PP (IN of) (NP (NP (DT the) (JJ therapeutic) (NN effect)) (PP (IN on) (NP (DT the) (NN disease)))))))) (. .))
